GLP-1 Medications: What to Know Before You Start

How GLP-1–based medicines work, what the trials showed, common side effects, and why stopping usually means weight returns.

Key takeaways

  • GLP-1–based medicines boost the body's fullness signals and are FDA-approved for chronic weight management.
  • Average results in trials were meaningful, but individual responses vary widely.
  • Stomach side effects are common early on and usually ease with slow dose increases.
  • Weight often returns after stopping, so starting is a long-term decision.

GLP-1–based medicines get a lot of attention. Some people come in excited to start one. Others are nervous, or have heard mixed stories from friends. Both reactions make sense. These are useful medicines, but they work best when you know what to expect before the first dose. This guide covers the basics in plain language.

What these medicines are and how they work

GLP-1 is a hormone your gut releases after you eat. It tells the brain you are getting full, slows how fast the stomach empties, and helps the body handle blood sugar. Medicines that act like GLP-1 turn up those signals. Many people notice they feel full sooner, think about food less, and find cravings quieter.

The FDA-approved GLP-1–based options for chronic weight management include semaglutide (Wegovy, as a weekly injection or a daily pill), tirzepatide (Zepbound), orforglipron (Foundayo, a daily pill) and liraglutide 3.0 mg (Saxenda). Tirzepatide acts on two gut hormone receptors, GIP and GLP-1. In general, adults may be candidates if they have a BMI of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure or prediabetes. 1 BMI is only a starting point, though. The full picture is your health history, your goals and your preferences.

In large trials, results were meaningful but varied a lot from person to person. In the STEP 1 trial, adults taking semaglutide 2.4 mg along with lifestyle support lost an average of 14.9% of their body weight over 68 weeks, compared with 2.4% on placebo. 2 In SURMOUNT-1, average weight reduction at 72 weeks ranged from 15.0% to 20.9% across tirzepatide doses, compared with 3.1% on placebo. 3 Averages hide a wide range. Some people respond strongly, some modestly, and a few very little.

Benefits go beyond the scale. In the SELECT trial, adults with heart disease and overweight or obesity, but without diabetes, had a 20% lower risk of heart attack, stroke or cardiovascular death on semaglutide than on placebo. 4

Side effects and safety

The most common side effects are in the gut: nausea, diarrhea, constipation, vomiting and reflux. They are usually mild to moderate and happen most often when the dose goes up. 2 That is why these medicines start at a low dose and increase slowly over several months. Eating smaller meals, stopping when you first feel full, and limiting greasy foods often helps.

Less common but important risks include gallbladder problems and pancreatitis. 1 These medicines are not used by people with a personal or family history of medullary thyroid cancer or a condition called MEN 2. They are not used during pregnancy, so tell your doctor if you are planning a pregnancy. Tirzepatide can make birth control pills less reliable for a while after you start or raise the dose, so ask about a backup method.

Let your care team know right away about severe or ongoing belly pain, repeated vomiting, or signs of dehydration.

What happens if you stop

Obesity is a chronic disease, and these medicines treat it the way blood pressure medicines treat high blood pressure. They work while you take them. In the STEP 4 trial, everyone took semaglutide for 20 weeks. Then some people kept taking it and others were switched to placebo. Over the next 48 weeks, people who continued lost a further 7.9% on average, while those who switched to placebo regained 6.9%. 5 In the STEP 1 extension, people regained about two-thirds of the weight they had lost within a year of stopping. 6

This is not a personal failure. It is biology. The body pushes back against weight loss, and the medicine was helping to hold that pushback in check. It does mean that starting a medicine is a long-term decision. Cost, insurance coverage and supply all matter. It is worth talking through the long-term plan before you begin.

Questions to ask before you start

  • Which medicine fits my health history, other medicines and goals?
  • How will we increase the dose, and what should I do if side effects are hard to manage?
  • How will we protect muscle while I lose weight?
  • What is the plan if I need to pause, switch or stop the medicine?
  • What will the medicine cost me over a year, and what are my coverage options?

A medicine is one tool in a broader plan. Eating enough protein, moving in ways you enjoy, strength activity, sleep and support all still matter. The goal is better health and a plan you can live with, not a number on a scale.

When to see a doctor

Talk with a doctor before starting any weight-loss medicine, and never use one without a prescription. Seek prompt care for severe belly pain, repeated vomiting or signs of dehydration.

Sources and references

  1. Grunvald E, Shah R, Hernaez R, et al. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2022;163(5):1198-1225. View source
  2. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. View source
  3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. View source
  4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. View source
  5. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425. View source
  6. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. View source

About the author

Dr. Alexis David, MD

Dr. Alexis David is a board-certified obesity medicine and family medicine physician and the founder of Premier Medical Weight Management in Bellevue, Washington.

This article is general education for adults and is not a substitute for personal medical advice. In an emergency, call 911.

Related articles

Protecting Muscle While Losing Weight

Some of the weight lost is muscle. Here's why that matters and how protein, strength activity and body composition checks can help.

Ready to talk about your weight and health?

Start with a private, judgment-free conversation about your goals and options.

Request an Appointment